Background {#Sec1}
==========

Atherosclerosis is a major cause of morbidity and mortality in systemic autoimmune diseases. Inflammation is central to the pathogenesis of atherosclerosis and is an important risk factor for vascular disease \[[@CR1]\]. An increase in the atherogenic index (AI) is associated with an increase in the atherosclerosis process \[[@CR2]\]. It is therefore important to treat cardiovascular risk factors, including dyslipidemia, in these patients.

The influence of tumor necrosis factor alpha (TNF-α) inhibitors on lipid profile \[[@CR3]--[@CR17]\] and AI \[[@CR3], [@CR5], [@CR7]--[@CR9], [@CR11], [@CR13], [@CR14], [@CR17]\] in patients with rheumatologic diseases has been examined in several studies (Table [1](#Tab1){ref-type="table"}), with inconsistent results. In some studies TNF-α inhibitors promoted an atherogenic lipid profile, while in others there was no such effect. None of the studies assessed the time-dependent impact of TNF-α inhibitors on the lipid profile of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and rheumatoid arthritis (RA) patients as a group.Table 1Literature on the influence of TNF-α inhibitors on lipid profileAuthorPublication yearPlaceFollow up (weeks)Patient numberDiseaseDrugResearch typeTC^a^TG^a^LDL^a^HDL^a^AI^a^Popa et al. \[[@CR4]\]2005The Netherlands233RAADAProspective↑↔↔↑Vis et al. \[[@CR6]\]2005The Netherlands669RAINFProspective↑↑Seriolo et al. \[[@CR8]\]2006Italy2434RAETA, ADA, INFProspective↑↔↑↔Allanore et al. \[[@CR10]\]2006France3056RAINFProspective↑↑↑Popa et al. \[[@CR9]\]2007The Netherlands5255RAINFProspective↑↑↔↔↑Tam et al. \[[@CR11]\]2007China1419RAINFProspective↑↑↑↑↔Peters et al. \[[@CR13]\]2007The Netherlands4880RAINFProspective↔↔↔↔Wijbrandts et al. \[[@CR16]\]2009The Netherlands5250RAADAProspective↔↔↔↔Mathieu et al. \[[@CR7]\]2010France1434ASETA, ADA, INFProspective↑↔↔↑↔Castro et al. \[[@CR12]\]2011Brazil315PAINFProspective↔↑↔↔Daïen et al. \[[@CR3]\]20122--5213 articlesRAETA, ADA, INFSystematic review, meta-analysis↑↑↔↑↔Curtis et al. \[[@CR5]\]2012United StatesMedian \> 2 years289RATNFiRetrospective↑↑↑↑↔Di Minno et al. \[[@CR14]\]20142--521707RATNFiMeta-analysis↑↑↔↑↔30 articlesPsAASSouto et al. \[[@CR15]\]201512--2425 articlesRAADA, INFSystematic review, meta-analysis↔↔↔↔Chen et al. \[[@CR25]\]2015Taiwan2448RAETA, ADAProspective↔↔↔↑↔Present study2016Israel104311RATNFiRetrospective↑↑↔↔↑PsAAS^a^Only significant changes (*p* ≤ 0.05) at the end of the follow-up period were included*TNF-α* tumor necrosis factor alpha, *TC* total cholesterol, *TG* triglycerides, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *AI*, atherogenic index, *RA* rheumatoid arthritis, *AS* ankylosing spondylitis, *PsA* psoriatic arthritis, *ADA* adalimumab, *INF* infliximab, *ETA* etanercept, *TNFi* TNF inhibitors↑ Increased,  ↔ Unchanged

Our objective was to assess the influence of TNF-α inhibitors treatment on the lipid profile and the AI of patients with AS, PsA, and RA at various time points up to 2 years of treatment.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A retrospective cohort analysis was conducted on the database of Clalit Health Services (CHS) in Haifa and Western Galilee districts in northern Israel. CHS is the biggest healthcare provider in Israel, with over 1 million members in this area (approximately 50 % of the total population of the region). CHS maintains a comprehensive computerized database with continuous input from pharmaceutical, medical, laboratory, and administrative computerized operators. The CHS database and our study cohort were described in a previous study \[[@CR18]\]. Briefly, the database for biological agents included in the Israeli 'health basket' contains diagnoses of specific rheumatic diseases as determined by a rheumatologist. The data are linked through a unique national identification number to the pharmaceutical, medical, and laboratory databases.

Medical charts of patients who met the following criteria were reviewed: minimum 18 years old; diagnosis under one of the codes---'rheumatoid arthritis', 'psoriatic arthritis', and 'ankylosing spondylitis'---and approval for biologic treatment included in the Israeli health basket; treated with TNF-α inhibitors between 2001 and 2011; began TNF-α inhibitors during the study period and were treated for at least 270 consecutive days; and had baseline lipid levels measured before starting treatment with TNF-α inhibitors and at least three lipid profile tests during the four time periods (0--6 months, 6--12 months, 12--18 months, and 18--24 months) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study flow. *TNF-α* tumor necrosis factor alpha, *TC* total cholesterol, *TG* triglycerides, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *RA* rheumatoid arthritis, *AS* ankylosing spondylitis, *PsA* psoriatic arthritis

The following data were collected: demographics (age, gender); rheumatologist diagnosis (RA, PsA, AS); comorbidities (diabetes, hypertension, hyperlipidemia, ischemic heart disease); type and dates of pharmacy-dispensed medication (TNF-α inhibitors, steroids, disease-modifying anti-rheumatic drugs (DMARDs), HMG CoA reductase inhibitors (statins), fibrates); diabetes treatment; and laboratory tests results---lipid profile that included total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). AI was calculated by the following formula: AI = log (TG/HDL), with TG and HDL expressed in molar concentrations \[[@CR2]\].

The patients were subdivided into three groups according to statin treatment:Patients not treated with statins.Patients who started statin therapy during the study period, after the initiation of treatment with TNF-α inhibitors.Patients who were treated with statins prior to and during the entire study period.

Patients from Groups 2 and 3 were included only if the type and dose of statin did not change during the study period. Patients treated with fibrates, which are known to reduce TG levels \[[@CR19]\], were excluded from the analysis in the TG group.

Statistical methods {#Sec4}
-------------------

Descriptive statistics are presented with continuous variables expressed as mean or median and standard deviation or standard error and categorical variables as frequencies and proportions. Comparisons of continuous patient characteristics among the three diagnostic groups (RA, PsA, AS) were performed by analysis of variance (ANOVA) or Kruskal--Wallis test, according to data distribution. Categorical variables were compared using the chi-square test.

The effect of TNF-α inhibitors therapy on lipid profile was assessed by comparing the levels of lipid particles at each time point with the baseline prior to treatment. Each lipid particle was analyzed in univariable and multivariable models, adjusted for the following study parameters: hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, PsA, AS), obesity, smoking, diabetes, hypertension, ischemic heart disease, gender, and age.

Comparisons at various times were performed by repeated-measures mixed-model ANOVA. This procedure takes into account the intracorrelation of repeated measurements carried out on the same subject and does not exclude subjects with incomplete data at follow-up. Stratification analysis by statin use was employed in a multivariable model in patients treated concomitantly with a TNF-α inhibitor and statins after adjustment for hyperlipidemia, hypertension, obesity, gender, and age.

The analyses were conducted with the PASW (SPSS) 19 statistical package (PASW Software Statistic, SPSS, Chicago, IL, USA). All statistical tests were two-sided and statistical significance was considered *p* ≤ 0.05.

Results {#Sec5}
=======

Study population {#Sec6}
----------------

Of the 689 patients treated with TNF-α inhibitors between 2001 and 2011, 311 met the inclusion criteria: 152 RA patients, 90 PsA patients, and 69 AS patients. The mean age of RA and PsA patients was higher (47.6 ± 19.3 and 50.2 ± 13.4 years, respectively) than that of AS patients (39.7 ± 15.2 years, *p* \<0. 01). As expected, there were more females in the RA group (74.3 %) than in the AS group (36.0 %, *p* \< 0.01). Corticosteroids were used more often in the RA group (58.7 %) than in the PsA and AS groups (29.2 % and 26.6 %, respectively, *p* \< 0.01). Diabetes, hyperlipidemia, and hypertension were more prevalent in the PsA group (19.0 %, *p* = 0.03; 52.2 %, *p* = 0.02; and 40.0 %, *p* = 0.02, respectively) than in the RA group (11.2 %, 37.5 %, and 36.2 %, respectively) and the AS group (1.4 %, 32.0 %, and 20.3 %, respectively). The incidence of ischemic heart disease did not differ significantly between the groups. Smoking was more prevalent in the AS group (45.0 %, *p* = 0.02) than in the RA and PsA groups (26.3 % and 30.0 %, respectively). Baseline values of TC and LDL did not differ significantly between the groups. HDL and TG levels were significantly lower in patients with AS. Higher TG levels were found in PsA patients. There was no difference at baseline between the three groups in the percentage of patients treated with statins (Table [2](#Tab2){ref-type="table"}). We excluded nine patients treated with fibrates from the TG group. These nine patients were treated with a constant dose of fibrates throughout the study and exhibited no significant changes in HDL and LDL values when TNF-α inhibitor was introduced; they were included in the TC, HDL, and LDL analysis.Table 2Baseline characteristics of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitisRheumatoid arthritisPsoriatic arthritisAnkylosing spondylitis*p* value(*n* = 152)(*n* = 90)(*n* = 69)Age (years)47.6 ± 19.350.2 ± 13.439.7 ± 15.2\<0.000150.052.038Baseline (mg/dl)TC^a,b^180.6 ± 37.6186.4 ± 35.2174.3 ± 38.9NS183.0185.0172.0HDL^a,c^53.92 ± 15.6751.23 ± 14.5146.40 ± 13.310.00352.0848.2543.38LDL^a,d^108.77 ± 25.63114.43 ± 22.31111.67 ± 34.09NS110.70117.14109.39TG^a,e^111.35 ± 53.44128.36 ± 57.32109.49 ± 53.870.0496.46119.00106.00GenderMale39 (25.7)26 (28.9)44 (64.0)\<0.0001Female113 (74.3)64 (71.1)25 (36.0)Statin treatmentTreated before and during treatment with TNF-α inhibitors25 (18.4)22 (24.4)9 (13.0)NSBegan treatment after beginning TNF-α inhibitors treatment18 (11.8)11 (12.2)8 (11.6)MedicationClassical DMARDs^f^93 (62.0)35 (39.3)20 (31.3)\<0.0001Steroids88 (58.7)26 (29.2)17 (26.6)\<0.0001SmokingCurrent or past40 (26.3)27 (30.0)31 (44.9)0.02Obesity27 (17.8)22 (24.4)6 (8.7)0.04Hyperlipidemia57 (37.5)47 (52.2)22 (32.0)0.02Diabetes17 (11.2)17 (18.9)1 (1.4)0.003Hypertension55 (36.2)36 (40.0)14 (20.3)0.02Ischemic heart disease21 (13.8)7 (7.8)4 (5.8)NSData presented as standard deviation with median below, or as *n* (%)^a^Because of missing values of lipid profile at various time points, the number of patients for each lipid profile test differed^b^TC: 152 RA, 90 PsA, and 69 AS patients^c^HDL: 113 RA, 74 PsA, and 46 AS patients^d^LDL: 122RA, 73 PsA, and 50 AS patients^e^TG: 120 RA, 71 PsA, and 49 AS patients^f^Classical DMARDs: leflunomide, azathioprine, cyclosporin, mercaptopurine, methotrexate, hydroxychloroquine, sulfasalazine*TC* total cholesterol, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *TG*, triglycerides, *TNF-α* tumor necrosis factor alpha, *DMARD* disease-modifying anti-rheumatic drug, *RA* rheumatoid arthritis, *AS* ankylosing spondylitis, *PsA* psoriatic arthritis, *NS* not significant

Lipid profile {#Sec7}
-------------

TC and TG levels increased following TNF-α inhibitor treatment, mainly during the first 6 months of treatment, and decreased thereafter but remained significantly higher than baseline at last follow-up (Table [3](#Tab3){ref-type="table"}). LDL and HDL levels did not change significantly following introduction of TNF-α inhibitors.Table 3Effects of TNF-α inhibitor treatment on lipid profileTimeBaseline value before treatment0--6 months6--12 months12--18 months18--24 monthsTotal cholesterol (mg/dl)Mean ± standard error180.85 ± 2.12188.12 ± 2.35183.80 ± 2.14184.48 ± 2.08184.88 ± 2.09*p* value\<0.0001NS0.0300.015Multivariate model^a^\
*p* value0.018NS0.0410.018HDL (mg/dl)Mean ± standard error51.8 ± 1.0753.55 ± 1.2151.06 ± 1.1352.04 ± 1.1852.05 ± 1.18*p* valueNSNSNSNSMultivariate model^a^\
*p* valueNSNSNSNSLDL (mg/dl)Mean ± standard error108.70 ± 1.55109.00 ± 1.92108.42 ± 1.76108.54 ± 1.75108.67 ± 1.70*p* valueNSNSNSNSMultivariate model^a^\
*p* valueNSNSNSNSTriglycerides (mg/dl)Mean ± standard error116.00 ± 3.55132.02 ± 4.63124.47 ± 3.95128.72 ± 4.17129.36 ± 4.32*p* value\<0.00010.005\<0.0001\<0.0001Multivariate model^a^\
*p* value\<0.00010.004\<0.0001\<0.0001Atherogenic index (LogTG/HDL)Mean ± standard error--0.032 ± 0.017--0.001 ± 0.02--0.01 ± 0.0190.009 ± 0.0180.004 ± 0.019*p* value0.0050.0430.0010.003Multivariate model^a^\
*p* value0.0070.040.0010.004^a^Adjusted for hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, AS, PsA), obesity, smoking, diabetes, hypertension, ischemic heart disease, gender, and age*TNF-α* tumor necrosis factor alpha, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *TG*, triglycerides, *NS* not significant, *RA* rheumatoid arthritis, *AS* ankylosing spondylitis, *PsA* psoriatic arthritis

The same pattern was found in the multivariate model after adjustment for hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, PsA, AS), obesity, smoking, diabetes, hypertension, ischemic heart disease, gender, and age.

Atherogenic index {#Sec8}
-----------------

The AI increased significantly following TNF-α inhibitor treatment (Table [3](#Tab3){ref-type="table"}). The same increase was found in the multivariate model after adjustment for hyperlipidemia, statin treatment, steroid treatment, rheumatic diseases (RA, PsA, AS), obesity, smoking, diabetes, hypertension, ischemic heart disease, gender, and age.

Co-administration of TNF-α inhibitors and statins {#Sec9}
-------------------------------------------------

The effect of the interaction between TNF-α inhibitors and statins on the various lipid parameters after adjustment for hyperlipidemia, hypertension, obesity, gender, and age reached statistical significance for LDL (*p* \< 0.01), TC (*p* = 0.02), and TG (*p* \< 0.01) values (Table [4](#Tab4){ref-type="table"}). No effect of the interaction was found in HDL values and therefore data were not analyzed further.Table 4Effects of TNF-α inhibitor treatment on lipid profile: stratification analysis by statin useNo statinsStatin treatment begun after initiating TNF-α inhibitor treatmentStatin treatment begun before and continued during TNF-α inhibitor treatmentTime periodMean ± standard error*p* valueMean ± standard error*p* valueMean ± standard error*p* valueTotal cholesterol^a^ (mg/dl)Reference183.73 ± 3.26188.96 ± 8.92182.04 ± 5.650--6 months188.63 ± 3.420.007208.22 ± 9.020.005188.78 ± 5.73NS6--12 months185.20 ± 3.29NS197.92 ± 8.74NS184.05 ± 5.60NS12--18 months187.77 ± 3.220.03198.55 ± 9.150.04180.42 ± 5.48NS18--24 months188.62 ± 3.34NS199.38 ± 8.460.01178.89 ± 5.14NSLDL^a^ (mg/dl)Reference103.13 ± 3.68112.10 ± 5.62119.97 ± 2.860--6 months106.01 ± 3.830.057123.42 ± 7.620.05107.84 ± 3.96\<0.0016--12 months105.63 ± 3.80NS115.35 ± 7.05NS108.26 ± 4.07\<0.00112--18 months106.85 ± 3.800.02119.67 ± 6.380.03101.85 ± 3.57\<0.00118--24 months107.70 ± 3.760.001115.89 ± 6.81NS104.02 ± 3.57\<0.001Triglycerides^a^ (mg/dl)Reference119.41 ± 9.75179.31 ± 19.96142.14 ± 9.890--6 months134.33 ± 10.24\<0.001223.91 ± 24.840.002147.33 ± 10.67NS6--12 months128.80 ± 10.050.02186.09 ± 20.47NS145.81 ± 10.15NS12--18 months135.89 ± 10.190.001181.31 ± 20.98NS149.60 ± 10.16NS18--24 months135.99 ± 10.20\<0.001194.68 ± 23.42NS146.72 ± 10.82NS^a^Adjusted for hyperlipidemia, hypertension, obesity, gender, and age*TNF-α* tumor necrosis factor alpha, *LDL* low-density lipoprotein, *NS* not significant

LDL levels rose higher than baseline values (103.13 ± 3.68 mg/dl) in patients treated with TNF-α inhibitors but not with statins, reaching statistical significance at 12--18 months (106.85 ± 3.80 mg/dl, *p* = 0.024) and 18--24 months (107.70 ± 3.76 mg/dl, *p* = 0.001). LDL in patients who began statins after the initiation of TNF-α inhibitors reached peak value at 6 months and 12--18 months. In contrast, LDL decreased significantly in patients who were treated with statins before starting TNF-α inhibitors and continued throughout the study: from 119.97 ± 2.86 mg/dl at baseline to 107.84 ± 3.96 mg/dl at 0--6 months (*p* \< 0.01), 108.26 ± 4.07 mg/dl at 6--12 months (*p* \< 0.01), 101.85 ± 3.57 mg/dl at 12--18 months (*p* \< 0.01), and 104.02 ± 3.57 mg/dl at 18--24 months (*p* \< 0.01) (Table [4](#Tab4){ref-type="table"}).

TC increased in patients not treated with TNF-α inhibitors or statins, from 183.73 ± 3.26 mg/dl at baseline to 188.63 ± 3.42 mg/dl at 0--6 months (*p* \< 0.01) and 187.77 ± 3.22 mg/dl at 12--18 months (*p* = 0.03). In patients who began statins after the initiation of TNF-α inhibitors, TC increased from 188.96 ± 8.92 mg/dl at baseline to 208.22 ± 9.02 mg/dl at 0--6 months (*p* \< 0.01), 198.55 ± 9.15 mg/dl at 12--18 months (*p* = 0.04), and 199.38 ± 8.46 mg/dl at 18--24 months (*p* = 0.01). TC values in patients treated with statins before initiation of TNF-α inhibitors did not change significantly.

The same pattern was observed in TG values, which increased significantly in patients treated with TNF-α inhibitors but not statins, and in patients who began statins after the initiation of TNF-α inhibitors, but only in the first 6 months. TG values increased, but not significantly, in patients treated with statins before TNF-α inhibitor initiation and during the whole study period (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec10}
==========

The demographic and clinical characteristics of our cohort are consistent with those described in the literature. AS patients were young and most were males, while RA patients were older, needed more treatment with corticosteroids, and most were females \[[@CR20], [@CR21]\]. A large meta-analysis by Armstrong et al. in 2013 \[[@CR22]\] showed an increased risk of metabolic syndrome in patients with psoriasis (odds ratio 2.26). According to our data, diabetes, hyperlipidemia, and hypertension were more prevalent in PsA patients than in RA and AS patients (Table [2](#Tab2){ref-type="table"}).

TNF-α inhibitors revolutionized the treatment of inflammatory arthritic conditions \[[@CR23], [@CR24]\]. In our study, TNF-α inhibitors significantly increased the AI, TC, and TG levels without significantly changing LDL and HDL levels. They also significantly increased LDL, TC, and TG levels in patients who were not treated with statins during the study. This was in contrast to the decrease in LDL levels in patients who were treated with statins prior to initiation of TNF-α inhibitors and continued treatment throughout the study.

A comparison of our results with those reported in the literature must take into account the different study designs. The 15 studies that assessed the effects of TNF-α inhibitors on lipid profile (Table [1](#Tab1){ref-type="table"}) \[[@CR3]--[@CR17]\] were of shorter duration, ranging from 2 to 30 weeks in nine studies \[[@CR4], [@CR6]--[@CR8], [@CR10]--[@CR12], [@CR15], [@CR17]\] and up to 52 weeks in six other studies \[[@CR3], [@CR5], [@CR9], [@CR13], [@CR14], [@CR16]\]. Follow-up in our study was 104 weeks. We conducted our analysis on pooled data of rheumatic patients in the ASPARA cohort while most of the published studies analyzed a single disease: 12 studies of RA, one study of PsA, and one study of AS. Sample size also varied: 15--80 patients in published studies \[[@CR4], [@CR6]--[@CR13], [@CR16], [@CR17]\] compared with 311 patients in our cohort. Six of the studies were performed in patients treated with infliximab (INF) alone, and the rest included data on different types of TNF-α inhibitors such as INF, etanercept (ETA), and/or adalimumab (ADA) (11 of 15 studies) \[[@CR3], [@CR4], [@CR6]--[@CR13], [@CR15], [@CR17]\]. Our study was performed in patients treated with INF, ETA, or ADA.

Our finding of a significant increase in TC levels following TNF-α inhibitor treatment (Table [3](#Tab3){ref-type="table"}) is in line with the results of 10 of the 15 studies mentioned \[[@CR3]--[@CR11], [@CR14]\]. Six of the 15 studies also reported an increase in TG levels following TNF-α inhibitors \[[@CR3], [@CR5], [@CR9], [@CR11], [@CR12], [@CR14]\], similar to our findings, while the other nine showed no significant changes in TG levels. Nine of the 15 studies studied the effect of TNF-α inhibitors on the AI \[[@CR3], [@CR5], [@CR7]--[@CR9], [@CR11], [@CR13], [@CR14], [@CR17]\]. Only one of them showed an increase in the AI \[[@CR9]\], similar to our results, while the others did not demonstrate significant changes of the AI. Concomitant treatment with statins, known to reduce TG, TC, LDL, and TNF-α levels \[[@CR25], [@CR26]\], could account for the lack of increase in TG levels and consequently the AI in those studies. Three studies that showed an increase in TG values included patients on drugs that affect the lipid profile, such as statins \[[@CR5], [@CR9], [@CR12]\]; the studies that did not show significant changes in TG levels did not include them in their calculations \[[@CR4], [@CR6]--[@CR8], [@CR10], [@CR13], [@CR15], [@CR16]\].

Our results showed no significant changes in the HDL and LDL values following TNF-α inhibitor treatment. The 10 studies from the literature \[[@CR3]--[@CR8], [@CR10], [@CR11], [@CR14], [@CR17]\] (Table [1](#Tab1){ref-type="table"}) that did report increased levels of HDL could be explained by the longer follow-up period in our study. Wijbrandts et al. \[[@CR16]\] reported a significant increase in HDL levels after 16 weeks of ADA treatment, although the level returned to baseline by the end of the 52-week study. Similarly, HDL levels in our study increased during the first 24 weeks and returned to near baseline levels later, although none of these changes was statistically significant (Table [3](#Tab3){ref-type="table"}). Like in our cohort, nine of the 15 studies that assessed the effects of TNF-α inhibitors on lipid profile \[[@CR3], [@CR4], [@CR7], [@CR9], [@CR12], [@CR14]--[@CR17]\] showed no significant change in LDL level following TNF-α inhibitor treatment. Because this could be due to concomitant treatment with statins, which can lower LDL values \[[@CR25], [@CR26]\], we tested whether there was an interaction between TNF-α inhibitor and statin treatment that affected the lipid profile.

LDL, TG, and TC levels increased significantly in patients treated with TNF-α inhibitors but not with statins. LDL and TC levels also increased significantly in patients who began statin therapy during the study, while TG increased significantly only during the first 6 months in this group. LDL values in patients treated with statins before and during the entire study period decreased significantly throughout the study. Thus, concomitant treatment with TNF-α inhibitor and statins may protect against the expected increase in LDL, helping reduce the cardiovascular risk in rheumatic patients in addition to treating the inflammatory component.

To our knowledge, no other study has demonstrated the benefit to LDL levels of adding statin treatment to TNF-α inhibitors. A meta-analysis of 31 observational studies showed that the TNF-α gene is involved in the pathogenesis of the metabolic syndrome (the *308A* variant of this gene has been associated with elevated levels of insulin and blood pressure) \[[@CR27]\]. Another study reported an association between polymorphisms of TNF-α (TNF-αG-238A) and LDL level \[[@CR28]\]. These investigators also found that *TNF-α-C-857T*---a polymorphism of the TNF-α gene promoter that increases transcription---is associated with increased LDL values and the formation of atherosclerotic carotid plaques in type 2 diabetes patients. Carriers of *TNF-α-C-857T* had significantly increased LDL values compared with noncarriers. There was no difference in LDL values in patients who were not treated with statins regardless of the carrier state of *TNF-α-C-857T*. In contrast, carriers of *TNF-α-C-857T* who were treated with statins had increased LDL levels compared with noncarriers \[[@CR29]\]. In other words, there is a link between statin therapy, TNF-α activity level, and LDL. These findings, together with our results, call for further research into the impact on LDL levels of adding statin treatment in patients with increased activity levels of TNF-α (as in carriers who harbor the *TNF-α-C-857T* polymorphism) compared with patients with low activity levels of TNF-α (such as those receiving TNF-α inhibitors).

There are some limitations in our study. In addition to being a retrospective and observational study without a control group, the study was conducted on a relatively small cohort of patients which included those who were taking various medications, including steroids and fibrates, and had illnesses such as diabetes that could affect lipid metabolism. We dealt with this limitation by constructing statistical models for each lipid profile parameter adjusted for possible confounders (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Being a retrospective study, follow-up data were not complete on all subjects; nevertheless, in order to include them in the analyses, we used repeated measures with mixed models that allow for unbalanced data and calculated the intracorrelation of repeated measurements carried out on the same subject. We estimated the drug intake according to pharma dispensed prescriptions. It would be interesting to evaluate the effects of long-term anti-TNF therapy on carotid artery US findings and its association with lipid profiles changes in further studies.

Conclusions {#Sec11}
===========

The study documents the real-life, long-term follow-up and treatment of RA, PsA, and AS patients being treated with TNF-α inhibitors. We found that this treatment promotes an atherogenic lipid profile most pronounced in patients not treated by statins, evidenced by a significant increase in the AI, LDL, TC, and TG levels. Statin therapy before and during treatment with TNF-α inhibitors may protect against the expected rise in LDL values. While there were negative changes in the lipid profile under TNF-α inhibitor treatment, they were relatively small and not statistically significant, and their clinical significance is unclear.

Coronary disease is the main cause of death in rheumatic diseases and the importance of reducing cardiovascular risk factors, including dyslipidemia, in these patients cannot be overemphasized. Prospective studies on the long-term effects of TNF-α inhibitors on lipid profile, with and without statins, are required to assess the cardiovascular risk in these patients.
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